Valuation: Indivior PLC

Market Cap 494.27Cr 433.23Cr 400.45Cr 368.3Cr 694.92Cr 48TCr 706.07Cr 4.79TCr 1.88TCr 23TCr 1.86TCr 1.82TCr 80TCr P/E 2026 *
12.8x
P/E 2027 * 11.2x
Enterprise Value 499.72Cr 438.01Cr 404.87Cr 372.36Cr 702.58Cr 48TCr 713.85Cr 4.84TCr 1.9TCr 24TCr 1.88TCr 1.84TCr 81TCr EV / Sales 2026 *
3.97x
EV / Sales 2027 * 3.46x
Free-Float
97.23%
Yield 2026 *
-
Yield 2027 * -
Change 5-day change 1-year change 3-year change Capi.($)
-1.82%-1.64% - - 494.27Cr
-2.73%-1.59%+52.60%+150.76% 1,05100Cr
-1.67%-3.05%+52.04%+48.41% 61TCr
-0.44%+2.11%+36.99%+78.09% 45TCr
-0.75%-1.46%+28.32%+22.33% 33TCr
-1.52%-0.95%+33.38%+38.39% 28TCr
-1.70%-3.54%+20.26%+17.88% 26TCr
-0.58%+1.78%-20.89%-38.37% 22TCr
-0.58%+1.34%+23.46%+56.62% 20TCr
-0.80%+1.69%+23.40%+67.14% 17TCr
Average -1.06%+0.58%+27.73%+49.03% 39.72TCr
Weighted average by Cap. -1.15%-0.22%+36.83%+72.70%

Financials

2026 *2027 *
Net sales 126.01Cr 110.45Cr 102.09Cr 94Cr 177.16Cr 12TCr 180.01Cr 1.22TCr 478.54Cr 5.95TCr 473.17Cr 462.85Cr 20TCr 131.24Cr 115.04Cr 106.33Cr 98Cr 184.52Cr 13TCr 187.48Cr 1.27TCr 498.41Cr 6.19TCr 492.82Cr 482.07Cr 21TCr
Net income 41Cr 36Cr 34Cr 31Cr 58Cr 4TCr 59Cr 401.52Cr 157.4Cr 1.96TCr 155.63Cr 152.24Cr 6.74TCr 47Cr 41Cr 38Cr 35Cr 66Cr 4.56TCr 68Cr 458.1Cr 179.58Cr 2.23TCr 177.56Cr 173.69Cr 7.69TCr
Net Debt 5.45Cr 4.78Cr 4.42Cr 4.06Cr 7.66Cr 525.55Cr 7.79Cr 53Cr 21Cr 257.14Cr 20Cr 20Cr 885.94Cr -40Cr -35Cr -33Cr -30Cr -57Cr -3.89TCr -58Cr -390.8Cr -153.2Cr -1.9TCr -151.48Cr -148.17Cr -6.56TCr
Logo Indivior PLC
Indivior Pharmaceuticals, Inc. is a global pharmaceutical company engaged in developing medicines to treat substance-use disorders (SUD). The Company provides treatment for addiction, including SUBLOCADE (buprenorphine extended-release) injection for subcutaneous use, a long-acting injectable (LAI) for opioid use disorder and OPVEE (Nalmefene) nasal spray for opioid overdose recovery. Its core products include SUBOXONE Film, SUBOXONE Tablet, SUBUTEX Tablet, OPVEE (nalmefene), and SUBLOCADE. SUBOXONE Film is a buprenorphine and naloxone sublingual film. SUBOXONE Tablet is a buprenorphine and naloxone sublingual tablet. SUBUTEX Tablet is a buprenorphine sublingual tablet. SUBOXONE Film, SUBOXONE Tablet, SUBUTEX Tablet, and SUBLOCADE are treatments for opioid use disorder (OUD). In addition to its commercially available products, its product pipeline includes two drug candidates for the treatment of OUD. It sells its products in the United States and in other selected areas of the world.
Employees
833
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-